Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Αποσπάσματα από τον έντυπο & ηλεκτρονικό τύπο => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 9 Ιουνίου 2016, 14:02:08
-
N Engl J Med 2016; 374:2009-2020May 26, 2016DOI: 10.1056/NEJMoa1600175
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
...............
.....................
Conclusions
Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923.)
.................................................
http://www.nejm.org/doi/full/10.1056/NEJMoa1600175#.V1lEqn5b_hw.facebook